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Specific peptide ligand recognition by modular interaction domains is essential for the fidelity of information flow
through the signal transduction networks that control cell behavior in response to extrinsic and intrinsic stimuli. Src
homology 2 (SH2) domains recognize distinct phosphotyrosine peptide motifs, but the specific sites that are
phosphorylated and the complement of available SH2 domains varies considerably in individual cell types. Such
differences are the basis for a wide range of available protein interaction microstates from which signaling can
evolve in highly divergent ways. This underlying complexity suggests the need to broadly map the signaling
potential of systems as a prerequisite for understanding signaling in specific cell types as well as various
pathologies that involve signal transduction such as cancer, developmental defects and metabolic disorders. This
report describes interactions between SH2 domains and potential binding partners that comprise initial signaling
downstream of activated fibroblast growth factor (FGF), insulin (Ins), and insulin-like growth factor-1 (IGF-1)
receptors. A panel of 50 SH2 domains screened against a set of 192 phosphotyrosine peptides defines an extensive
potential interactome while demonstrating the selectivity of individual SH2 domains. The interactions described
confirm virtually all previously reported associations while describing a large set of potential novel interactions that
imply additional complexity in the signaling networks initiated from activated receptors. This study of pTyr ligand
binding by SH2 domains provides valuable insight into the selectivity that underpins complex signaling networks
that are assembled using modular protein interaction domains.Lay abstract
Every cell in our body is an immensely powerful computa-
tional device capable of integrating vast amounts of data
from intrinsic and extrinsic cues and responding with re-
markable fidelity. What underlines this computational
power are not static wires, but dynamic interactions that
leverage the finite number of genes to generate an almost
infinite number of combinatorial interactions between
protein components. In the post-genomics era, mapping
these interactions represents a next frontier. The sum* Correspondence: pdnash.uchicago@gmail.com
1Ben May Department for Cancer Research, The University of Chicago,
Chicago, IL 60637, USA
2Committee on Cancer Biology, The University of Chicago, Chicago, IL 60637,
USA
Full list of author information is available at the end of the article
© 2012 Liu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortotal of all permitted interactions is referred to as the
potential interactome. In any given cell, only a subset of
potential interactions will be enabled and this defines the
selective differences in signalling between tissues. Under-
standing the whole provides insight into the information
processing power of the system and may suggest new ave-
nues for therapeutic intervention to treat diseases caused
by faults in signal processing mechanisms. This study out-
lines the potential interactome for initial signalling events
from the insulin receptor, insulin-like growth factor
receptor and all four members of the fibroblast growth
factor receptor family. These systems are essential for
human development and dysfunctional signalling has
been implicated in a wide range of human diseases
including diabetes, many cancers, Alzheimer's disease,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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connections are reported between 50 SH2 domain-
containing proteins and 192 phosphopeptide nodes on
13 signal-initiating proteins. This verified almost every
interaction described in the past 25 years and adds an
extensive new data, providing a step towards fathom-
ing the intricacies of differential cell communication
between various tissues and disease states.
Introduction
Signaling immediately downstream of receptor tyrosine
kinases (RTKs) is accomplished in large part by the re-
cruitment of phosphotyrosine (pTyr) interacting proteins
to sites of tyrosine phosphorylation on the activated
receptors and their associated scaffold proteins [1-3]. A
given RTK may contain on the order of 10–20 phos-
phorylatable tyrosine residues with additional sites avail-
able on associated scaffold proteins resulting in a large
number of potential sites for recruiting binding partners.
The majority of phosphotyrosine interacting proteins
contain a conserved Src homology 2 (SH2) domain [4].
The SH2 domain is the classic archetype for the large
family of modular protein interaction domains that serve
to organize a diverse array of cellular processes [5,6].
SH2 domains interact with phosphorylated tyrosine-
containing peptide sequences [7-11] and in doing so
they couple activated protein tyrosine kinases (PTKs) to
intracellular pathways that regulate many aspects of cel-
lular communication in metazoans [12,13]. The human
genome encodes 111 SH2 domain proteins [14,15] that
represent the primary mechanism for cellular signal
transduction immediately downstream of PTKs. As one
might expect, SH2 domain proteins play an essential role
in development and have been linked to a wide array of
human malignancies including cancers, diabetes, and
immunedeficiencies [14,16].
Despite the importance of SH2-mediated signaling in
human disease, our understanding of their interactions
remains far from complete. Direct experimental measure-
ment of binding partners has typically focused on specific
interactions driven by hypotheses relating to the precise
signaling events under investigation. This yields a set of
high quality, but inevitably sparse data. Certain pTyr pro-
teins and SH2 domains are extensively studied while others
are more arcane. Nonetheless, the SH2-mediated interac-
tions reported over 25 years of intensive study provide a
solid foundation for validating high-throughput datasets.
SH2 domain interactions are almost always phosphor-
ylation dependent as roughly half of the binding energy
is devoted to pTyr recognition [17,18]. Despite this, SH2
domains preserve substantial specificity for peptide
ligands, recognizing residues adjacent to the pTyr, par-
ticularly those at positions +1 to +5 C-terminal to the
critical pTyr [19-21]. This is achieved in part by use ofcomplex recognition events that effectively combine the
use of motifs and sub-motif modifiers [11]. Specifically,
SH2 domains recognize targets not only through permis-
sive residues adjacent to the phosphotyrosine that con-
stitute binding motifs, but also by making use of
contextual sequence information and non-permissive
residues [22] to define highly selective interactions with
physiological peptide ligands. The specificity of SH2
domains enables their use as tools to profile the global
phosphotyrosine state of cells or tissues [23-27], without
a priori knowledge of the specific target proteins or pep-
tides. Profiling signaling using SH2 domains has direct
implications to diagnosis and guiding therapeutic deci-
sions as the patterns obtained can be used to classify
tumors [27]. The ligand specificity of many SH2
domains has been evaluated using approaches including
synthetic peptide libraries [19,28,29], oriented peptide li-
braries [20,30] and phage display [31]. Information of
this type is often described by position-specific scoring
matrices (PSSM), and allows programs such as ScanSite
and Scoring Matrix-Assisted Ligand Identification
(SMALI) to predict potential binding motifs [20,21].
Recruitment of SH2 domain proteins to phosphorylated
sites is a dynamic process and is by no means predeter-
mined by the phosphorylation event alone. Each tyrosine
site on a scaffold (including sites on receptors that recruit
SH2 domains) can be phosphorylated or unphosphory-
lated. The phosphorylated site can either be free or occu-
pied by one of its potential binding partners. Each possible
assembly of interaction partners on a given scaffold repre-
sents an interaction microstate [32-35]. The actual popu-
lated interaction microstates from which signaling
develops is a function of many factors, including protein
expression levels, local concentration, and the probability
that a given site is phosphorylated. Thus, distinct signaling
networks may originate from the same scaffold or recep-
tor in different cell types. This is also true under condi-
tions of aberrant expression of signaling components that
are a common occurrence in pathologies such as cancer.
Thus, accurate and well-annotated potential interactomes
that represent the aggregate available interaction micro-
states are a valuable resource that opens the door to inter-
preting studies of signaling in different cell types or under
conditions of altered protein expression. As the Human
Protein Atlas detailing subcellular localization data and
expression data makes clear, cell lines and tissues vary
widely and often in unanticipated ways in terms of protein
expression [36]. All of this suggests that detailed potential
interactomes may provide substantial benefit in under-
standing cell-type specific signaling.
Herein, we describe a potential interactome obtained
using addressable peptide arrays consisting of 192
physiological peptides from the insulin (Ins), insulin
growth factor 1 (IGF-1) and fibroblast growth factor
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50 SH2 domains. This set represents a broad sam-
pling of the SH2 domains extant in the human gen-
ome. The results of this study map a range of potential
phosphotyrosine-dependent interactions within the FGF
and Ins/IGF-1 pathways. These signaling systems have
relevance to understanding complex multi-tissue patholo-
gies such as diabetes and cancer as well as in normal
physiology and development. This study confirms 44 of 54
previously described interactions. In addition, we report
an extensive set of novel interactions. Validation of 60 bin-
ary interaction pairs was conducted using the orthogonal
method of solution binding measured by fluorescence
polarization. The binding motifs obtained for each SH2
domain closely match those reported in a number of inde-
pendent studies. Protein co-precipitation experiments, or
endogenous phosphorylation upon receptor stimulation,
were further used to validate a number of interactions.
The results of this study highlight the available pool of po-
tential SH2-mediated interactions with these 13 major
signaling proteins and serve as a first step in under-
standing signaling microstate variations. Interactive
figures and additional information may be found at
http://www.sh2domain.org.
Results
Peptide arrays for SH2 interactions within the FGF/Ins/
IGF-1 signaling pathways
The use of addressable peptide arrays is a reproducible
and semi-quantitative approach that has been exten-
sively validated for studying protein interactions with
peptide ligands [37-39]. To investigate connections be-
tween SH2 domain proteins and their putative phos-
phorylated docking sites on cell surface receptors, we
developed addressable arrays consisting of 192 phospho-
tyrosine peptides. This peptide set was assembled using
71 phosphotyrosine peptide motifs corresponding to all
of the cytoplasmic tyrosine residues within the FGF
receptors (FGFR1-4), insulin receptor (InsR) and IGF-1
receptor (IGF-1R) (Figure 1A). Activation of these recep-
tors results in the phosphorylation of associated scaffold
proteins, and so 75 phosphotyrosine peptides corre-
sponding to a comprehensive list of tyrosine residues
within insulin receptor substrates (IRS-1 and IRS-2) and
fibroblast receptor substrates (FRS-2 and FRS-3) were
included. In addition, 33 phosphotyrosine peptides were
incorporated from the downstream signaling proteins
PLC-γ1, p130Cas (BCAR1) and p62DOK1. Finally, a set
of 12 positive control peptides corresponding to 19
reported interactions with 15 SH2 domains for which
equilibrium dissociation constant (KD) values span a
range from low nM to 50 μM were incorporated to aid
in validating the results. These control peptides provide
a reference and establish the empirical cut-off fordesignated binding interactions (Table 1). No discrimin-
ation was made against peptides on the basis of reported
phosphorylation state in order to examine a diverse and
unbiased set of motifs. The resulting set of 192 phospho-
tyrosine peptides and their corresponding position in the
proteins of origin is noted in Additional file 1: Table S1.
Addressable arrays were synthesized as membrane-
bound 11-mer peptides using the SPOT synthesis tech-
nique [40-42]. While the majority of SH2 domains
recognize residues C-terminal to the phosphotyrosine in
their cognate peptide ligands, additional contacts be-
tween SH2 domains and residues N-terminal to the
phosphotyrosine are observed for the SH2 domain of
Sh2d1a (SAP) [43] and cannot be ruled out in other
cases. Peptides were synthesized with six flanking resi-
dues C-terminal to the phosphotyrosine and four resi-
dues N-terminal to the phosphotyrosine.
To assess the potential network of SH2 domain inter-
actions we selected 50 SH2 domains representing 28 of
the 38 families of SH2 domains (Figure 1B) all of which
we have previously shown can be expressed and purified
[23]. These include a number of extensively studied SH2
domains (Src, Grb2, PLCγ), as well as a number of less
studied SH2 domains from proteins such as Shd, She,
Shf, Slnk (Sh2d6), Sh2d1a (SAP), Sh2d1b (Eat-2), and
Brdg1. To address potential variability in specificity
within families we employed all members from the SHB,
CRK, GRB2, SRC and ABL families (families are indi-
cated with complete Capitalized lettering).
SH2 domains were arrayed as GST fusion proteins and
detected using anti-GST primary antibodies and near-
infrared labeled secondary antibodies. In an effort to
present a dataset with minimal false positives, we chose
an empirical cutoff based on the array average across all
peptide spots to classify interactions (Figure 1A). In
cases where the intensity of the signal for an individual
SH2-domain binding event exceeded the mean intensity
of all the peptides on the membrane by three-fold were
scored as “array positives” [22]. Non-binding was judged
in cases where the intensity of a spot was less than the
mean intensity of all spots on the membrane and these
were scored as “array negatives”. Peptides with signal in-
tensities between 1X and 3X mean were scored as
“indeterminate” and ascribed as neither array positive
binding interactions nor array-negative non-binders.
Analysis of the distribution of SH2 domain interactions
per phosphopeptide revealed that our dataset possessed
a bimodal distribution, with a significant number of pep-
tides binding to many SH2 domains (Additional file 2:
Figure S2). This signature may be indicative of promis-
cuity differences between phosphopeptides or there may
be a subset of peptides which interact in a nonspecific
fashion with either the GST fusion tag or one of the





































































































































































Figure 1 Probing interactions between SH2 domains and physiological peptide ligands at a systems level. (A) A representation of a SPOT
peptide array containing 192 phosphotyrosine peptides including control peptides (black) and peptides from the 13 proteins present on the array
indicated by their represented colors. SPOT peptide arrays were incubated with 250nM GST-SH2 domain as indicated. Interactions were detected
using anti-GST antisera and Alexa-680-labeled anti-mouse secondary antibody and the intensity of signals recorded using LiCor Odyssey. (B)
Neighbor-Joining Tree of all 121 SH2 domains. Highlighted in blue are the 50 SH2 domains selected across different families for this study. (C)
Peptide arrays using SPOTS is a semi-quantitative method for measuring protein domain-pTyr peptide interactions. The dissociation constants (KD)
were measured between 60 interaction pairs presenting interactions determined using peptide arrays as greater than 3X the mean, between 1
and 3X the mean and less than 3X the mean. The mean KD value for each group is marked with a black line.
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ciated with identifying false-positives, we probed three
separate arrays with three separate preps of the GST fu-
sion tag alone. Potentially non-specificly interacting pep-
tides (so-called ‘sticky’ peptides) were identified as any
that bound to GST with above mean intensity in two
out of three separate trials. This approach identifies any
peptides which interact with GST or either of the recog-
nition antibodies, a known confounding factor for down-
stream analysis [44]. This conservative approach allows
us to score many significant peptides as ‘binders’ which
may have been indeterminate before when incorporatingthe ‘sticky’ peptides into the array average. This resulting
in discarding 40 peptides representing 382 potential
interaction pairs as non-selective and resulted in a data-
set of substantially higher quality.
Validation by orthogonal assays and literature-verified
interactions
To verify the binding results obtained from addressable
peptide arrays we employed an orthogonal method of
determining SH2 interactions with peptide ligands. We
measured the dissociation constants of 60 binary SH2-
peptide pairs in solution by fluorescence polarization
Table 1 Literature confirmed interactions 39 array-positive interactions were experimentally verified or confirm
previously reported interactions while 23 array-negative interactions empirically suggest a threshold corresponding to














Crk Yes N.A. [87] Crkl, Hck
EDDGpYDVPKPP Cbl (Y774) Crk Yes N.A. [88] Crkl
Hck Yes N.A. [89,90] Fgr, Src, Yes
AEDVpYDVPPPA p130Cas (Y362) Crk Yes KD = 0.545 μM [87] Src, Hck, Fyn
GLDEpYDEVPMP B3AT (Y921)* Nck1 Yes KD = 0.06 μM [91] *Similar to the TIR10 peptide (EHIpYDEVAAD). Fer
DDPSpYVNVQNL ShcA (Y426) Grb2 Yes KD = 23nM [92,93] Gads, Grap
Grb2 Yes KD = 53 ± 8nM [94]
ADNDpYIIPLPD PDGFRb (Y1021) Plcγ-N Yes KD = 0.65 -
2.2nM1
[95] 1Tandem SH2 domains of PLCG1 were tested against a
tandem phospho-peptide of PDGFRβ Y1009/Y1021.
Plcγ-C Yes KD = 0.65 -
2.2nM1
[95-97]; Brk
Plcγ-C Yes KD = 4.1 ± 0.8
μM
[98]
Vav1 Yes N.A. [99]
PI3K_N No ID50 = 45 ± 14
μM
[79] Below Threshold
SLTIpYAQVQKA SLAM (Y280) Sh2d1b Yes KD = 131nM [100]
HDGLpYQGLSTA CD150 (Y142) Shc1 No KD = 50 μM [101] Below Threshold
STVEpYSTVVHS gp130/IL-6
Receptor (Y759)




Src Yes KD = 0.55-0.8
μM
[19] Blk, Brk, Fer, Fgr, Hck, Lyn, Nck1, Shc1, Yes
Lck Yes KD = 1.3 ± 0.2
μM
[103]
SDDDpYDDVDIP HPK1 (Y379) Nck1 Yes N.A. [104] Fer, SLNK (similar to BLNK and SLP76)
TRDIpYETDpYpYR InsR
(Y1185,89,90)
Plcγ_C Yes N.A. [105] Crk, Crkl, Fer, Grb7, PI3K1_C
EDLSpYGDVPPG IRS-1 (Y151) Nck1 No N.A. [106] 1.76X Mean Abl1, Blk, Fyn, Lck, Lyn, Sh2d1b, Shc1, Ship2,
Slnk, Yes
ELSNpYICMGGK IRS-1 (Y465) Ptpn11_N No IC50 = 48 ± 16
μM
[107] Below Threshold, 0.9X Mean
SIEEpYTEMMPA IRS-1 (Y551) Ptpn11_N No IC50 = 11 ± 1.0
μM
[107] Below Threshold, 0.56X Mean
GSGDpYMPMSPK2 IRS-1 (Y612) PI3K1_N No ID50 = 0.7-1.1
μM
[79] 2Peptide Y632 (GSGDpYMPMSPK) on IRS-1 is similar to
Y612 (TDDGpYMPMSPG) on IRS-1.
DPNGpYMMMSPS IRS-1 (Y662) Ptpn11_N No IC50 = 96 ± 13
μM
[107] Below Threshold, 0.54X Mean
SPGEpYVNIEFG IRS-1 (Y896) Ptpn11_N Yes IC50 = 4.8 ± 1.0
μM
[107,108] Abl2, Blk, Dapp1, Grb7, Itk, Mist, PI3K1_N, PI3K1_C,
PTPN11_N, PLCγ_C, Rasa1_N, Rasa1_C, Sh2b, Sh2d1b,
Shb, Shf, Shd, She, Syk_C, Vav1, Yes
Grb2 Yes KD = 35nM [92,108,109] Gads, Grap
APVSpYADMRTG IRS-1 (Y1012) Ptpn11_N No KD = 110 ± 23
μM
[107] Below Threshold, 0.59X Mean
NGLNpYIDLDLV IRS-1 (Y1179) Ptpn11_N Yes3 KD = 3.0 ±
0.60nM
[95,108,110] 3Tandem SH2 domains of PTPN11 was used to bind to
the tandem motif of IRS-1
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Table 1 Literature confirmed interactions 39 array-positive interactions were experimentally verified or confirm
previously reported interactions while 23 array-negative interactions empirically suggest a threshold corresponding to
a KD of approximately 5 to 10 μM for this data set (Continued)
Ptpn11_N Yes IC50 = 1.1 ± 0.5
μM
[107] Abl1, Ptpn11_N, Plcγ_C, Rasa1_N, Shb, Shf, Shd, She, Yes
Fyn No N.A. [46] 0.45X Mean
DLSApYASISFQ IRS-1 (Y1229) Ptpn11_N No IC50 = 25 ± 4.2
μM
[107] Below Threshold, 2.78X Mean
Ptpn11_C No N.A. [108] 1.59X Mean
Fyn No N.A. [46] 0.48X Mean
GGEFpYGYMTMD IRS-2 (Y540) Plcγ_C Yes N.A. [111] Dapp1, Grb7
PNGDpYLNVSPS IRS-2 (Y766) Grb2 Yes N.A. [112] Sh2d1b, Vav1
SNQEpYLDLSMP FGFR1 (Y766) Shb No N.A. [113] Similar peptide to Y760 of FGFR3 but has weak binding,
0.45X Mean
Plcγ No N.A. [55] PLCγ_N – 0.52X Mean
PLCγ_C – 0.21X Mean
THDLYMIMREA FGFR3 (Y724) Sh2b No N.A. [114] 0.44X Mean
STDEpYLDLSAP FGFR3 (Y760) Sh2b No N.A. [114] 0.46X Mean
VSEEYLDLRLT FGFR4 (754) Plcγ No N.A. [115] SHD
QVHTpYVNTTGV FRS2 (Y196) Grb2 Yes N.A. [116] Abl2, Gads, Grap, PI3K1_C
NKLVpYENINGL FRS2 (Y306) Grb2 Yes N.A. [116] Grap, Grb7, Sh2d2a
ALLNpYENLPSL FRS2 (Y349) Grb2 Yes N.A. [116] Abl1, Abl2, Gads, Grap, Grb2, Grb7, PI3K1_C, Sh2d2a,
Sh3bp2
PMHNpYVNTENV FRS2 (Y392) Grb2 Yes N.A. [116] Gads, Grap
RQLNpYIQVDLE FRS2 (Y436) Ptpn11_N Yes N.A. [117] Itk, Mist, PLCγ_C, Rasa1_N, Shb, Shd, She, Syk_C
NPGFpYVEANPM PLCγ1 (Y783) Plcγ_C No N.A. [118] PLCγ_C at 1.03X mean; Zap70_N
EQDEYDIPRHL p130Cas (Y234) Crk Yes N.A. [87] Brk, Crkl, Fyn, Lck, Lyn, Shc1, Yes
PQDIYDVPPVR P130Cas (Y249) Crk Yes N.A. [87] Crkl, Zap70_N
WMEDpYDYVHLQ p130Cas (Y664) Nck1 Yes N.A. [87,119] Bcar3, Brk, Crk, Crkl, Dapp1, Fer, Grb7, Matk, PI3K1_N,
Rasa1_N, Rasa1_C, Sh3bp2
Bmx Yes N.A. [120] Itk
Src No KD = 25-46nM [119,121] 2.45X mean
Lck No N.A. [121] 2.03X mean
PPALpYAEPLDS p62DOK1 (Y296) Rasa1_N Yes N.A. [122] Abl1, Nck1, Vav1, Zap70_N
Rasa1_C Yes N.A. [122]
QDSLpYSDPLDS p62DOK1 (Y315) Rasa1_C Yes N.A. [122] Abl1, Blk, Crk, Lck, Lyn, Nck1, Src, Zap70_N
EDPIpYDEPEGL p62DOK1 (Y362) Nck1 Yes N.A. [123] Blk, Hck, Lck, Lyn, Shc1, Src
Abl1 Yes N.A. [124]
KEEGpYELPYNP p62DOK1 (Y398) Rasa1_C Yes N.A. [123] Abl1, Blk, Brk, Fgr, Fyn, Hck, Lck, Lyn, Nck1, Sh2d1b, Shc1,
Ship2, Src, Vav1, Yes
Rasa1_N Yes N.A. [123]
A set of control peptides with previously reported SH2 domain targets was included on each array. We further identified a set of literature-reported interactions
between specific peptides present on the arrays and SH2 domains used in this study. Peptide sequence is indicated along with the source protein and
corresponding position of the relevant phosphotyrosine residue. SH2 domains that were expected to bind to each peptide are noted along with the observed
array-positive status. Measured equilibrium dissociation values (KD) or relative affinity (IC50) values reported in the literature are noted. Additional array-positive
SH2 domains identified as interacting with each peptide are also indicated along with explanatory comments
N.A. – No Affinity Determined, # - IC50 Relative Affinities.
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References Comments and other SH2 domains bound
AEDVpYDVPPPA p130Cas
(Y362)
Abl2 No KD = 14 μM This Study
Crk Yes KD = 0.35 μM This Study;
[87]
Fyn, Hck, Src
CrkL Yes KD = 0.99 μM This Study
Nck1 Yes KD = 0.93 μM This Study
Ptpn11_N No KD > 50 μM This Study
Shc1 No KD = 32.8 μM This Study
Ship2 No KD = 16.5 μM This Study Below Threshold (1.91X Mean)
SPGEpYVNIEFG IRS-1
(Y896)
Abl1 No KD = 7.48 μM This Study Blk Dapp1 Fgr Grb7 Itk Mist Pi3k1_N Pi3k1_C Plcg1_C
Ptpn11_N Rasa1_N Rasa1_C Sh2b Sh2d2a Shb Shf Shd She
Syk_C Vav1 Yes
Abl2 No KD = 3.66 μM This Study
Crk No KD > 20 μM This Study




PI3K1_N Yes KD = 2.68 μM This Study
Plcg2_C Yes KD = 2.92 μM This Study
Ptpn11_N Yes KD = 2.08 μM This Study
IC50 = 4.8 ± 1.0
μM
[107,108]
Sh2b Yes KD = 3.58 μM This Study
Src No KD = 2.21 μM This Study
Tenc1 No KD = 24 μM This Study
NGLNpYIDLDLV IRS-1
(Y1179)
Abl1 No KD = 22.2 μM This Study Itk Plcg1_C Rasa1_N Sh2b Shb Shf Shd She Yes
CrkL No KD > 50 μM This Study
Grb2 No KD > 50 μM This Study
PI3K1_N No KD = 15 μM This Study
Ptpn11_N Yes3 KD = 3.0 ± 0.60nM [95,108,110]
3Tandem SH2 domains of Ptpn11 was used to bind to the
tandem motif of IRS-1
Ptpn11_N Yes IC50 = 1.1 ± 0.5
μM
[107]
Src No KD = 9.94 μM This Study
GVSEpYELPEDP FGFR1
(Y463)
Brk Yes KD = 0.38 μM This Study
Crk No KD = 44 μM This Study
CrkL No KD > 50 μM This Study
Itk Yes KD = 2.74 μM This Study
Nck1 Yes KD = 2.45 μM This Study
Rasa1_N No KD = 1.54 μM This Study
Rasa1_C No KD > 17 μM This Study
Src No KD = 6.85 μM This Study
Vav1 Yes KD = 1.87 μM This Study
STDEpYLDLSAP FGFR3
(Y760)
Abl2 No KD = 27 μM This Study
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Table 2 Measured affinity values (Continued)
PI3K1_C No KD = 2.14 μM This Study
Plcg2_N No KD > 50 μM This Study
Plcg2_C No KD = 7.49 μM This Study
Ptpn11_N No KD =25 μM This Study
Sh2d1b No KD = 5.3 μM This Study 2.52X Mean, Lck
Shb No KD > 50 μM This Study Below Threshold, 0.23X mean
Rasa1_C No KD > 17 μM This Study
KEEGpYELPYNP p62DOK1
(Y398)
Abl1 Yes KD = 5.77 μM This Study Blk Brk Fgr Fyn Hck Itk Lck Lyn Nck1 Pi3k1_N Sh2d1b Shc1
Ship2 Src Vav1 Yes
Abl2 Yes KD = 3.47 μM This Study
Brk Yes KD = 0.42 μM This Study
Crk No KD = 23.7 μM This Study
Fer No KD = 13.3 μM This Study
Fgr Yes KD = 2.04 μM This Study
Itk Yes KD = 5.43 μM This Study
Nck1 Yes KD = 4.37 μM This Study
PI3K1_N Yes KD = 1.85 μM This Study
PI3K1_C No KD = 13 μM This Study
Ptpn11_N No KD > 50 μM This Study
Rasa1_N Yes KD = 0.41 μM This Study
N.A. [123]
Rasa1_C Yes KD = 1.39 μM This Study
N.A. [123]
Sh3bp2 No KD = 1.68 μM This Study
Shc1 Yes KD = 5.74 μM This Study
Src Yes KD = 5.06 μM This Study
Vav1 Yes KD = 4.73 μM This Study
Select SH2-peptide interaction pairs were confirmed by fluorescence polarization solution-binding. Additional affinity values from published sources have been
included and listed accordingly.
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array-positive interactions were of high affinity (range
0.18 μm – 5.8 μM, median KD = 2 μM), while array
negative interactions were demonstrably lower affinity
(median KD > 30 μM) (Figure 1C). This suggests a low
false-positive rate and indicates that array-positive inter-
actions correspond to high affinity binding events at a
high frequency.
Probing of arrays individually with each of 50 SH2
domains provides a snapshot of SH2 specificity (Figure 2A).
As we have previously shown, this method is highly repro-
ducible [22]. Independent peptide arrays and protein pre-
parations reveal high reproducibility for the select SH2
domains (Shb, Ship2, Sh3bp2) (Figure 2B). To confirm
interactions between full-length proteins we performed a
set of GST-SH2 pull-down experiments of CHO stably
expressing InsR and IRS-1 with or without stimulation
with insulin (Additional file 2: Figure S4). These lysates
were incubated with GST-SH2 domains and precipitatedusing glutathione-agarose beads to identify SH2 domains
that were capable of precipitating phospho-IRS1 or phos-
pho-InsR. This confirmed previously described inter-
actions such as those involving the PI3K_C, Shp2_N
and Fyn (as well as related Src and Itk) SH2 domains
[45-47]. In addition, interactions observed on the pep-
tide arrays were confirmed for Rasa1, Vav1, and Abl2
and PLC-γ1.
The literature is a rich source of detailed interactions
that provide potential validation. Since the discovery of
the SH2 domain in 1986 [48], detailed study has uncov-
ered a large set of SH2 interactions. Any high-
throughput technique would expect to capture most of
these interactions, and failure to do so may be taken as
evidence of false-negative results. Each of our address-
able peptide arrays included a set of 12 designed control
peptides for which 22 reported interactions covered a
range of KD values. In addition, we noted 43 interactions
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B
Figure 2 Addressable peptide arrays reveal SH2 domain selectivity. (A) 50 SPOT arrays panned against 50 GST-SH2 domains reveals the
highly selective nature of SH2 domain phosphopeptide interactions. Interactions were detected using anti-GST antisera and Alexa Fluor-680-
labeled anti-goat secondary antibody and the intensity of signals recorded using LiCor Odyssey. (B) Two separate peptide arrays were probed
with independent SH2 domain preparations for three SH2 domains (SHB, SHIP2, SH3BP2). The scatter plot reveal some variability between the
independent SPOT experiments yet revealing a strong correlation coefficient (R2).
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MINT [50], BIND [51], HPRD [52], and DIP [53]. Of the
22 designated control interactions, 18 were noted as
array-positive (Table 1). Of the remaining four expected
interactions, three have measured affinities, and in all
cases the equilibrium dissociation constant is weaker
than 16 μM. All of the array-positive interactions for
which affinity is reported have KD values stronger than
4.1 μM. Thus, this control set suggests an approximate
threshold of binding in the range of 10 μM± 5 μM. Of
the 43 database-reported interactions, most were array
positive and of those that were not array-positive, a
number were just sub-threshold and judged to be inde-
terminate (Table 1). The ability to recapitulate the vast
majority of known (literature-reported) interactions and
to verify novel interactions by orthologous methods is
indicative of a high quality dataset [54].
Reconciling conflicts with other datasets
As noted above, this study performs well in terms of re-
producing the literature reported interactions between
the 50 SH2 domains tested and the 13 proteins repre-
sented on the addressable arrays (Table 1). A handful of
differences with literature-reported interactions must, by
necessity, be reconciled. Our assumption is that a high-
throughput (HTP) study such as this one should capture
upwards of 85% of known (literature reported) interac-
tions and that results that differ from low throughput
studies described in the literature should be subject to
further testing to identify the nature of the discrepancy
and reveal any weakness in the HTP dataset [55]. We
examined a set of potential discrepancies and found that
in each case our dataset held up well. For instance,
FGFR1 Y-766 (SNQEpYLDLSMP) is reported to bind to
PLCγ1 in a pTyr dependant manner based on muta-
tional analysis of FGFR1 [55,56]. We tested the PLCγ2
SH2 domain with an analogous peptide from FGFR3
Y-760 (STDEpYLDLSAP) and failed to detect any inter-
action. Direct measurement of peptide binding to either
the PLCγ2_N or PLCγ2_C SH2 domain by fluorescence
polarization in solution also failed to detect an interaction,
supporting the results on the array (Table 2, Additional
file 2: Figure S3). This may imply that either this is a bind-
ing event specific to PLCγ1 (and not PLCγ2), or that the
interaction reported at the level of the full-length
protein may be more complex, perhaps requiring sec-
ondary contact sites that are not available within the
context of the short peptide used in the current study.
In several other cases, literature-reported interactions
that were array-negative turned out to be interactions
with IC50 or KD values above 10 μM (Table 1). It is
likely that a few low micromolar or even sub-micromolar
binding events could be assigned as array-negative in
our study due to synthesis yield heterogeneity and thefact that we are limited to arraying at one concentra-
tion (0.25 μM in this study). We decided to design an
empirical reporting scheme that was conservative, sac-
rificing many true positives in order to limit false positives,
which would have naturally arisen in the process of
trying to minimize false negatives. We have made an
effort to limit false negatives to those of lower affin-
ity, and we are aware of no instance in our dataset
of a sub-micromolar affinity interaction being scored
as array-negative.
Many high-affinity interactions, such as the interac-
tions between the Src and Lck SH2 domains and
p130Cas pY-664, fell into our array-indeterminate set
(1x-3x mean), likely due to the synthesis efficiency and
accessibility of these particular peptides and the semi-
quantitative nature of the system. Indeed, many of the
peptide-SH2 interactions that fall in the indeterminate
set are likely to be real binders. Some surprising differ-
ences between SH2 domains can be reconciled this way.
For instance, comparing between the Abl1 and Abl2
SH2 domains there is a significant difference in array
positive interactions between the two. This is surprising
considering the sequence similarity between the two
domains. Because of the heterogeneities inherent in this
study design as indicated above and the similarities be-
tween the two proteins, discrepancies of this sort likely
represent false negatives. In total, the limited number of
incongruities between the current data set and the litera-
ture are thus largely reconcilable.
A high-throughput binding study reported interactions
between a large set of SH2 domains and phosphopep-
tides within four receptor tyrosine kinases (including
IGF-1R and FGFR1) overlaps with the present study
[57]. Our dataset only validates 5 of 51 of these interac-
tions and describes 6 additional interactions not
reported in that study. This disagreement is in contrast
to the high degree of consensus between the present
study and a wide range of previous studies (Table 1).
We examined a number of the interactions reported by
Kaushansky A et al. using a combination of an ortholo-
gous experimental approach, comparison to consensus
binding motifs, and literature validation. As noted
above, SH2 domains have well described binding motifs
and adhere to these remarkably well in the current
study. Kaushansky A et al. report a large number of
interactions that do not approximate the binding motifs
to which the corresponding SH2 domains are known to
be capable of binding. In addition, SH2 domains make
use of contextual sequence information and non-
permissive residues that block binding in order to im-
prove selectivity [22]. For example, the Grb2 family has
a very strong preference for an asparagine residue at
the +2 position and will not tolerate a proline residue
at the +3 position [19-22]. Kaushansky A et al. report a
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contain the required permissive residues, and further-
more many that contain strong non-permissive residues
(Additional file 2: Figure S7 and Table S3). Similarly,
Crk SH2 requires a +3 Leu or Pro yet this motif is ab-
sent in many of the Crk SH2 binding peptides reported
by Kaushansky et al. Indeed, the 46 interactions
reported by Kaushansky et al. that we fail to confirm
overwhelmingly contain peptides that lack conformity to
the consensus motifs to which the cognate SH2
domains are known to interact [19,20,29]. In addition, a
number of apparent “hub” peptides reported in Kaush-
anky et al. contain cysteine residues (eg. FGFR1 pY-583,
FGFR1 pY-605, FGFR1 pY-730), and the interactions
were probed in the absence of reducing agents [57,58].
In the present study, binding was assayed in the pres-
ence of 1 mM DTT and peptides containing cysteine
residues were substituted with serine [59]. Kaushansky
et al. provide no corroboration of their results by either
orthogonal assay or literature validation, while the
present study provides extensive corroboration.
Even in the cases where our data overlap, the
reported apparent KD values reported by Kaushansky
et al. appear inconsistent with direct measurements
conducted using well controlled solution binding
measured by fluorescence polarization [57]. For ex-
ample, Kaushanskyet al. report a KD of 175nM for
the interaction between Rasa1-N-SH2 and FGFR1 pY-463
while we measured a KD of 1.54 μM by fluorescence
polarization (Additional file 2: Figure S7), Additionally,
there are 6 interactions that we report that are not noted
by Kaushansky et al. We picked one of these binary
pairs at random, the interaction between Crk SH2
and FGFR1 pY-463, and tested binding in solution.
We measured KD of 380 nM for this interaction, val-
idating this binding event.
Taken as a whole, comparisons with the literature val-
idate the results presented in this study. Non-array-
positive literature-reported interactions tend to fall into
three categories: 1) low affinity interactions; 2) near
misses that are array-indeterminate and thus just below
threshold; or 3) cases where orthogonal measurement
confirms no interaction at the level of the individual
SH2 domain and 11-mer phosphopeptide. Comparison
with an SH2 domain array study reveal limitations in
that technique and suggest that SH2 domain arrays on
glass substrates may suffer from a high rate of false posi-
tive and false negative interactions. This is consistent
with results from the same group investigating PDZ do-
main binding using a similar protein microarray method
which concluded that the technique resulted in a false
positive rate of approximately 50%, and poor corres-
pondence between array-estimated and solution-binding
measured equilibrium-dissociation values [60-62].Metadata-rich interaction maps
Probing arrays with 50 SH2 domains identifies a total of
529 array-positive interactions, together with 5949 array-
negative and 1122 indeterminate SH2-ligand pairs.
Array-positive interactions between SH2 domains and
pTyr sites map the potential SH2 interactome. The
connections between SH2 domains and InsR, IGF-1R,
IRS-1, IRS-2, FGFR1, FGFR2, FGFR3, FGFR4, FRS2 and
FRS3 together with p130Cas, PLCγ1 and p62DOK1
highlight a wide range of putative SH2 interactions
within the immediate FGF and Ins/IGF-1 signaling net-
works (Figure 3). The prediction of novel interactions
comes with the inherent caveat that a given SH2 protein
would need to be co-expressed with its interaction part-
ner. For example, Grap and Gads are expressed only in
certain hematopoietic cells [63,64]. Interactions recorded
for the SH2 domains of Gads and Grap are not useful
for predicting interactions in other cell types but may be
considered as supporting data for the interactions of the
closely related Grb2 SH2 domain. The similar specificity
of the SH2 domains of Grb2, Gads and Grap results in
an overlapping set of target peptides where the inde-
pendent binding of all three SH2 domains increases our
confidence that this peptide is in fact a high-quality lig-
and for this class of SH2 domains.
To enhance the interaction maps derived the current
study, we incorporated multiple layers of additional data
gleaned from a variety of sources. Specific phosphopep-
tides reported in the PhosphoSite database are noted for
each of the 13 target proteins in Figure 3 (Additional file 1:
Table S1) [65]. Reported phosphorylation remains a
moving target, particularly as certain sites may be phos-
phorylated only in certain tissues or transiently upon
recruitment of specific kinases [33]. In cases where
phosphorylation of a tyrosine residue has been reported,
we assume that region to be solvent accessible and capable
of interactions. If phosphorylation has not been reported
solvent accessibility may be considered as a minimal
threshold for phosphorylation and SH2 domain binding.
This is with the caveat that certain residues, such as the
activation loop tyrosine in the kinase domain of the InsR
and IGF-1R are buried in the inactive state but become
phosphorylated and solvent exposed in the activated state.
The phosphorylated and exposed activation loop is then
able to bind to SH2 domains [66]. Given the dynamic
nature of protein structures and the ability of buried
residues to become exposed upon structural rearrange-
ment, one cannot presuppose that buried residues never
become exposed. Nonetheless, solvent accessibility pro-
vides an additional level of support for potential phospho-
dependent interactions in cases where phosphorylation
has not been reported. Existing structures provide a
greater level of confidence in such interactions while
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Figure 3 (See legend on next page.)
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Figure 3 High-resolution interaction maps detail an SH2 domains potential interactome. A phosphotyrosine interactome for 13 proteins
involved in FGF-family and Insulin-family signaling and 50 SH2 domain partners. Phosphotyrosine peptides are indicated by their position within
their host protein and color-coded as either PhosphoSite reported phosphorylation sites (yellow); sites not reported as phosphorylated (red); sites
not reported to be phosphorylated but where a closely related site on a paralogous protein is known to be phosphorylated (red/yellow); or the
peptide was discarded as non-specific (black). Interactions between the vertices of SH2 domains and phosphopeptides identified in this study are
indicated as edges (lines) and color-coded according to the level of support provided by previous studies: if the precise phosphorylation site has
been reported to interact with the noted SH2 domain the edge is denoted in red. A black line is representative of proteins that are reported to
interact defined by interaction databases including HPRD, BIND, MINT and DIP, but the site of interaction is unknown. SH2 interactions not
confirmed by literature but whose binding is greater than 3X mean on the array are represented with grey lines.
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Surface algorithm was employed to calculate the access-
ible molecular surface [67,68] of each tyrosine residue
within structure files PDBID:1IRK, 2DTG, 1P4O, 1K3A,
1IRS, 1QQG, 2FGI, 2PVF, 2PSQ, 1XRO, 2YS5, 2YT2,
2 V76, 1WYX, 1HSQ, and 2HSP that represent regions
of InsR, IGF-1R, IRS-1, FGFR1, FGFR2, FRS2, FRS3,
p62DOK, p130Cas and PLCg in various conformations
(Additional file 2: Table S4). Sites that fell below the
threshold of the minimally accessible phosphorylation site
(excluding the activation loop tyrosine) are marked in
orange text for the residue number in Figure 3. Many
of these sites are also excluded as non-specific inter-
action sites, likely reflecting their hydrophobic nature.
Inclusion of structural data, where available, makes
use of a significant resource to interpret potential pTyr
interaction data.
Previously reported specific SH2-phosphopeptide inter-
actions confirmed in this study (Table 1) are highlighted
as red lines (Figure 3) and represent the highest confi-
dence interactions. Noted as black lines are cases for
which protein-protein interactions have been reported in
MINT [50], BIND [51], HPRD [52], and DIP [53], without
reference to specific binding sites or direct involvement of
an SH2 domain. Interactions noted in the current study
that are not listed in any of the major interaction data-
bases, are represented as grey lines.Position weighted matrices define physiological ligand
specificity
To represent the specificity of SH2 domains in this study
we define position weighted matrices (PWMs) based on
the array-positive peptides. PWMs such as the position-
specific scoring matrix (PSSM) [21] are a well-established
method to describe biding motifs. In a PWM, each matrix
column describes the probability that a given amino acid
will be found at that ligand position. The PWM may also
be visualized as a sequence logo [69] (Figure 4A). The 192
physiological peptides represented on the arrays in this
study do not conform to a random distribution of
residues at each position. To compensate for this the
matrices were corrected for the prevalence of aminoacids residues at each position in the total data set. In
addition, the absence of binding to a given peptide may
provide data on inhibitory effects of specific residues.
For instance, lack of binding may result from either the
absence of critical permissive residues or from the pres-
ence of inhibitory residues at specific positions [22]. To
make use of both array-positive and array-negative data
we corrected for frequency of occurrence of a given
residue at each position using the array-positive pep-
tides (posPWM). This is compared to a PWM of the
expected frequency of all peptides, excluding non-
specific peptides (exPWM). The scoring matrix that
results from subtracting exPSSM from posPSSM
expresses the deviation observed in the array-positive
data from that of all specific peptides on the array. We
term this the expectation-deviation scoring matrix
(EDSM).
EDSM½  ¼ posPWM½ – exPWM½ 
By expressing differences between peptides that bind
specifically and the peptide set as a whole, the EDSM
attempts to compensate for any inherent bias arising in
the relatively small set of non-random peptides drawn
from physiological proteins. The EDSM for each SH2 in
this study is visualized using sequence logos (Additional
file 2: Figure S5) and condensed into a generalized state-
ment of physiological specificity in the form of a regular
expression (Table 3). A distance matrix comparing the
EDSMs for the physiological specificity of the SH2
domains describe families of SH2 domains related by
their preference for physiological ligands (Additional file
2: Figure S6). This is represented as an unrooted tree of
SH2 domain specificity (Figure 4B). Six classes of general
specificities are displayed among the SH2 domains tested
in this study revealing similarity among SH2 domains
within the same family (eg Grb2, Gads, Grap) and across
different families (Sh2d1b, Ship2) but also subtle differ-
ences (eg Abl1 and Abl2). Although the EDSM is
informed by both permissive and non-permissive effects,
the limited dataset afforded by the addressable arrays in
this study limits the utility of the resulting matrices for



















































































Figure 4 Specificity for physiological peptides defines functional groups of SH2 domains. (A) Grb2 SH2 domain positive peptides are
highlighted and then represented as an EDSM logo. See Figure S5 for EDSM logos of all tested SH2 domains. (B) An unrooted dendrogram
clusters families of SH2 domains related by similar binding patterns. A distance matrix between EDSMs was computed and used to generate an
unrooted distance tree (see Figure S6). This is artistically represented as a dendrogram with general specificity information overlaid and functional
classes denoted by branch color.
Liu et al. Cell Communication and Signaling 2012, 10:27 Page 14 of 23
http://www.biosignaling.com/content/10/1/27Discussion
The analysis of SH2-mediated interactions with peptide
ligands representing the receptors and substrate proteins
of the insulin, IGF-1 and FGF systems described herein,
reconstructs the set of potential phosphotyrosine-
mediated interactions that determine the capacity of
these systems to recruit signaling proteins upon activa-
tion. The potential interactome outlines the possiblesignaling states that may participate in signaling. Among
the factors that determine the possible signaling net-
works initiated by activated receptors are 1) the available
set of SH2 proteins expressed in specific cells; and 2) the
capacity of phosphorylated receptor and scaffold sites to
recruit those SH2 proteins. The 111 SH2 domain pro-
teins extant in the human genome vary extensively in
their tissue and cell specific expression [15,36]. In some
Table 3 Specificities obtained using Physiological Ligands
SH2 Domain Specificity
ABL1 [pY] [D/E/S] [D/E] [P/N/D/E]
ABL2 [pY] [V] [N/Q]
BLK [pY] [D/E/φ] [D/E/L] [P/I]
BRK [pY] [D/E] [X] [D/E/φ]
CRK [D] [X] [pY] [D] [V/L] [P] [P]
CRKL [D] [X] [pY] [D] [φ] [P] [P/R]
DAPP1 [pY] [X] [X] [D/E/φ] [E]
FER [D/E] [D/E] [pY] [D/G] [D/E] [φ]
FGR [E] [P/D/E] [X] [pY] [D/E/G] [X] [D/E/φ] [Y]
FYN [pY] [X] [D/φ] [φ]
GADS [pY] [V] [N]
GRAP [pY] [V/E] [N]
GRB2 [pY] [V/E] [N]
GRB7 [pY] [E] [N/Y]
HCK [D/E] [D/P] [X] [pY] [D/E/G] [D/E/φ] [P/I/L]
ITK [pY] [φ] [X] [D/φ]
LCK [pY] [D/E/G] [D/E] [P/L] [P]
LYN [pY] [D/E/G] [D/E] [P] [P]
MIST [pY] [φ] [ζ] [φ] [D/E] [φ]
NCK1 [pY] [D/E] [E/L] [P/V]
PI3K1_N [pY] [V/D] [X] [I/M/V]
PI3K1_C [pY] [V/M/E] [N/T/M] [M]
PLCG1_C [pY] [φ] [X] [D/E]
PTPN11_N [pY] [φ] [X] [φ] [D/E] [φ]
RASA1_N [pY] [φ] [X] [D/φ]
RASA1_C [pY] [X] [X] [D/E/φ]
SH2B [pY] [X] [X] [D/E/φ]
SH2D1B [pY] [X] [X] [φ]
SH2D2A [pY] [E] [N/T] [D/φ]
SH3BP2 [pY] [D/E] [N] [V]
SHB [pY] [φ] [X] [φ] [D/E] [φ]
SHD [pY] [φ] [X] [φ] [D/E] [φ]
SHE [pY] [φ] [X] [φ] [D/E] [φ]
SHF [pY] [φ] [X] [φ] [D/E] [φ]
SHC1 [pY] [D/E/G] [D/E/φ] [φ]
SLNK [pY] [G/D/V] [D/T] [D/φ]
SRC [D/E] [X] [X] [pY] [D] [D/E/φ] [P/I]
SYK_C [φ] [pY] [V] [X] [D/E/φ] [D/E]
TENC1 [pY] [E]
VAV1 [pY] [V/E/L] [X] [P]
YES [pY] [D/E/G] [D/E/φ] [φ]
Table 3 Specificities obtained using Physiological Ligands
(Continued)
ZAP70_N [P] [X] [pY] [X] [X] [ψ/φ]
The general specificity information is obtained from the arrays is expressed in
a regular expression form. Amino acid residues are indicated by their single-
letter codes. Groups of amino acids are noted as ϕ = hydrophobic residues
(Val, Ile, Leu, Phe, Trp, Tyr, Met); ψ = aliphatic residues (Val, Ile, Leu, Met);
ζ = polar residues (Asn, Gln, Ser, Thr, Glu, Asp, Lys, Arg, His).
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define highly tissue-specific signaling networks such as
those in B- and T-lymphocytes [14,15]. Among the 38
SH2 families, 33 possess at least one gene duplicate
allowing a duplicate copy to acquire new functions such
as specialized tissue functions or novel scaffolding cap-
abilities [70]. The expression of a family member in one
tissue may perform a redundant function to its paralog in
another tissue but may also diverge in terms of functions
(Additional file 2: Table S5). The potential interactome for
SH2 domains indicates many cases of potential overlap in
binding, resulting in pTyr sites that may act as hubs for
multiple interactions or serve distinct binding functions in
cases where the SH2 complement varies in different cells.
The varied potential interaction permutations, or micro-
states, in turn, are the basis for highly cell-specific signal-
ing outcomes from discrete signal inputs [34]. In simple
terms, differences in the available phosphorylated tyrosine
sites as well as in the expression of SH2 domain proteins
themselves has the potential to furnish related but distinct
signaling events in responses to the same input signal
(Figure 5A). Currently the phosphorylation dataset avail-
able from PhosphoSite and PhosphoELM provide only a
static view of receptor and scaffold phosphorylation. Even
within a cell, the available complement of pTyr sites and
locally available SH2 domain proteins may vary over the
lifetime of a signal. Protein interaction microstates may
differ according to the intensity of ligand stimulation and
change as signaling complexes move within the cell, for
instance as receptors are internalized on signaling endo-
somes (Figure 5B). For example, Grb10 and Grb14 are
closely regulated adaptor proteins that share similar func-
tions by binding to InsR and negatively regulating insulin
signaling. While both genes share high expression in the
pancreas, expression varies among adipose, liver and the
heart (Figure 5C). However, little is known about the tem-
poral and spatial dynamics between these two adaptors.
Recently studies utilizing multiple reaction monitoring
(MRM) mass-spectrometry has been applied to the Grb2
adaptors to map the dynamic interaction states upon vari-
ous growth factor stimulation [71]. Analyses of this type
will allow us to better dissect the vast number of micro-
states among different tissues. Thus, potential interac-
tomes represent crucial datasets to interpret cell and
tissue specific signaling events. This is particularly relevant
in human development and diseases such as cancer in
Figure 5 (See legend on next page.)
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Figure 5 Tissue co-expression and microstate of the Insulin/IGF-1 system. Protein interaction microstates across different cell types and
across time and space. (A) Co-expression between receptors and SH2 domains can influence the microstate of a specific tissue.
(B) Phosphorylation of receptors under stimulation conditions can determine the temporal and spatial events of SH2 ligand binding within a cell.
(C) Hierarchical clustering of the insulin responsive tissue expression levels for human SH2 domain-containing genes.
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expressed, sometimes by several orders of magnitude. In
such pathologies, the primary signaling pathways may be
titrated out and novel, normally non-physiological path-
ways may become activated. For instance, IGF-1R is either
overexpressed or hyperphosphorylated and deregulated in
a range of cancers and is currently one of the most studied
molecular targets in the field of oncology yet direct target-
ing of IGF-1R has proven problematic due to it’s wide
range of important physiological functions [72-74]. Under
conditions of hyperphysiological abundance of IGF-1R
pTyr sites available for SH2 binding, the potential interac-
tome suggests the potential for non-canonical pathways to
become activated, perhaps hinting at novel targets for
therapeutic intervention.
Even in normal physiological circumstances of healthy
tissues, the potential interactome may inform our under-
standing of tissue-specific signaling events. A variety of
tissues can respond to insulin stimulation, including
adipose, muscle, pancreas, liver, brain etc. [75,76]. SH2
domain-containing proteins vary widely in their expres-
sion in various cells and tissues (Figure 5C). While this
likely represents only a piece of a much larger puzzle, it
is conceivable that some of the observed tissue-specific
responses and downstream signaling differences may re-
late to the available complement of SH2-containing sig-
naling proteins and their ability to interact with available
pTyr sites. In this way, the potential interactome and
cell-specific expression combine to determine effective
signaling networks.
Consensus motifs and co-evolution
The interaction data also reveals the specificity of 50
SH2 domains for a set of physiological peptides. Typical
binding motifs for SH2 domains describe the residues at
positions +1 to +4 C-terminal of the essential phospho-
tyrosine [77-79]. SH2 domain peptide binding motifs
have been described for a wide range of SH2 domains
using peptide library approaches [19,20,29]. Binding
motifs obtained from peptide library approaches repre-
sent optimal solutions unconstained by physiological
parameters such as the confounding effects of kinases
recognition or structural influences of native proteins.
The motifs described herein represent binding to ‘real-
world’ peptides and thus stand as a relevant contrast
to peptide-library based data. However it should be
noted that this dataset corresponds to a potential
physiological interactome. Because all of the peptideshaven’t been confirmed to be phosphyorylated in vivo,
our interaction maps are best used in conjunction
with the expanding mass spectrometry literature and
their associated databases.
Broadly speaking, the SH2 consensus binding motifs
identified from interactions observed using addressable
arrays of physiological peptides are remarkably similar to
the motifs described using peptide library approaches
(Table 3). Yet binding specificities observed for physio-
logical phosphotyrosine peptide ligands may in some
cases represent more than the specificity of the isolated
SH2 domain. The EDSM position weighted matrices
noted in Additional file 2: Figure S5 reveal a number of
cases in which the residues outside of the conventional
window of residues at positions +1 to +4 appear to influ-
ence binding. Longer contact regions have been noted
for certain SH2 domains in the past, though these are
generally exceptions to the rule. For instance, the SH2
domain of SH2D1A/SAP binds to an extended peptide
in the SLAM receptor comprised of residues −2 to +3
and shows a diminished dependence on phosphorylation
of the tyrosine for binding [43]. Physiological peptide
ligands co-evolve to allow recognition by their cognate
SH2 domain partner, while also acting as competent
substrates for their cognate kinases. In some cases, the
observed specificity for physiological peptide ligands
may therefore represent an amalgam of SH2 specificity,
kinase recognition, and other factors. This may, for ex-
ample, explain the apparent observed preference of the
Crk SH2 domain for an Asp residue at the −2 position.
The presence of an aspartic acid residue at the −2 pos-
ition does not appear to contribute to Crk SH2 domain
binding (Figure 4B), however, this may instead reveal a
signature for a distinct event such as kinase recognition
for a specific subset of physiological peptides. Indeed, a
large number of tyrosine kinases have reported prefer-
ence for acidic residues preceding the target tyrosine
residue [80,81]. Not surprisingly, acidic residues are
commonly observed in the EDSM logos for the SH2
domains (Additional file 2: Figure S5). In addition to act-
ing as kinase substrates and SH2 domain binding sites,
the peptide motif must also presumably be surface
exposed, and potentially disordered prior to binding, and
these factors may also contribute to the overall physio-
logical peptide motif. Combining multiple motifs in
computational searches has been shown to markedly in-
crease predictive accuracy [82], suggesting that the in-
clusion of indirect components such as kinase specificity
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tions. While the current data set is relatively small in
size, larger sets of data identifying physiological peptide
interactions may provide useful data for investigating the
overlapping influences of multiple events required for
functional signaling based on overlapping motifs.
In our analysis we find that peptides reported to be
phosphorylated in PhosphoSite are significantly more
likely to have one or more SH2 domain-binding partners
than peptide nodes that are not currently known to be
phosphorylated. This is not surprising given that evolu-
tionary pressure may be exerted to conserve critical
binding sites. Conversely, given the specificity of SH2
domains, the chances of an SH2-interacting peptide oc-
curring by chance within a non-phosphorylated peptide
may be assumed to be relatively low. The more residues
that must be specified to stipulate binding, the lower the
probability is that this will occur spontaneously within
a non-phosphorylated sequence. If only one key resi-
due supported by one of two secondary residues was
capable of allowing an SH2 domain to bind, then the
chances of randomly generating an SH2 binding site
centered around a given tyrosine residue are less than
one in a hundred. Given the specificity observed for
SH2 domains in this study, the likelihood of a ran-
dom sequence encoding an SH2 domain ligand appears
rather limited. The appearance of a small number of
highly connected peptide nodes on sites not currently
known to be phosphorylated raises the question of whether
SH2 domain-binding might serve as means of predicting
phosphorylation. Perhaps highly connected peptide hubs
such as IRS1 Y-151, IRS2 Y-184, FRS3 Y-287 and FRS3
Y-322 predict phosphorylation. ScanSite predicts the
first three of these sites as kinase substrates, while the se-
quence surrounding FRS3 Y-322 is identical to a known
phosphorylation site on FRS2, suggesting that these
may indeed turn out to be phosphorylated under ap-
propriate conditions.
A high degree of selectivity for physiological ligands
may itself be an outcome of evolutionary pressures, as
has been noted for yeast SH3 domains. The Sho1 SH3
domain recognizes a binding peptide in Pbs1, and no
other SH3 domain in the yeast genome cross-reacts with
the Pbs1 peptide. SH3 domains from other species that
have not been under evolutionary pressure to ignore this
site exhibit less selectivity for the Pbs1 peptide [83]. A
high degree of specificity among human SH2 domains,
combined with cell-specific expression is consistent with
the notion that evolutionary pressures drive selectivity of
protein-ligand interactions.
Comparison to the literature
In the quarter century since the SH2 domain was first
described [48,84], hundreds of interactions have beendescribed between SH2 domains and phosphotyrosine
peptides. In many cases these have been subject to in-
tensive biophysical analysis yielding a considerable set of
bonafide interactions against which HTP studies can be
validated. Placing new studies within the context of the
extant literature is particularly important for systems
levels studies for which validation is inherently limited.
In the case of the 50 SH2 domains and 192 peptides
included in this study, we confirmed 60 interactions by
the orthologous method of fluorescence polarization.
We compared our results to those reported in previous
studies. In the case of carefully controlled studies that
examine SH2 interactions, our results closely match the
reported interactions (Table 1). However, our results did
not match well against one large-scale interaction study
conducted using SH2 domain arrays (Additional file 2:
Table S3) [57]. Our results suggest that the SH2 protein
micro-array results may suffer from high false-positive
and false-negative rates and that the reported KD values
are likely inaccurate. This is consistent with other stud-
ies suggesting that protein microarray data is semi-
quantitative and subject to false-positive results [60],
particularly in the absence of orthologous validation
Several lessons may be taken from such results and
suggest a set of standards that could be universally
applied in future high throughput studies of protein-
peptide interactions and these are explored in detail
elsewhere [54]. First, proteins are fundamentally prob-
lematic in that they may easily lose binding activity.
A set of positive controls is thus essential and should
be present in every assay. Only about half of the SH2
domains express well as fusion proteins from bacteria
[23]. The rest suffer from poor expression and lack
reproducible binding activity, suggesting that any use
of these SH2 domains in high-throughput in vitro
binding studies may yield erroneous results. The
present study used only 50 SH2 domains that have
previously been shown to express well and exhibit
good solubility and reproducible binding. A second
issue relates to validation by orthologous method, to
which the current study examines 60 binary pairs by
the orthogonal method of solution phase fluorescence
polarization binding, as well as a smaller set by GST-
pulldown. A third consideration is agreement between
HTP datasets and existing literature. Well-controlled
studies reporting peptide-binding motifs for SH2
domains provide a wealth of data. SH2 domains bind
to relatively specific motifs [19,29], and these provide
excellent validation tools. Apparent interactions that
do not match the known binding motifs are a cause
for concern and should be further validated. As noted
in Table 1, the dataset described in this study is in
strong agreement with literature-reported interactions,
and the variations can largely be rationalized.
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In examining SH2 domain interactions, we followed a
systematic approach for systems-level interactome stud-
ies using orthologous validation and literature curation
as a means of enhancing confidence in the experimental
dataset. This results in a large set of high-confidence
interactions that outline the potential interactome between
50 SH2 domains and 192 phosphopeptide sequences
covering 13 proteins involved in FGF, Insulin, and
IGF-1 signaling. The development of a detailed poten-
tial interactome for this set of signaling components
represents an early step towards a more detailed under-
standing of cell-specific signaling networks. This stands
to deepen our understanding of tissue-specific and disease-
specific signaling networks that are predicated upon
the varying and inevitably complex interpretation of
the potential interactome by the available expressed
interaction partners.Experimental procedures
Plasmids and recombinant proteins
A comprehensive list of 121 SH2 domains contained in
111 human proteins [14] served as the starting point for
the assembly of a large set of SH2 domain clones. The
cDNA clones for SH2 domains were obtained from
ATCC except for those noted otherwise. A complete list
of source DNA and SH2 clones is shown in Additional
file 3: Table S2. SH2 domains were cloned into pGEX-
2TK (Amersham Pharmacia) and verified by DNA se-
quencing. GST-fusions of SH2 domains were expressed
in E. coli strain BL21 (Stratagene) at 37°C overnight and
induced with 1 mM IPTG for 3 hours. Cells were centri-
fuged, resuspended in PBS and lysed by sonication. The
cellular fractions were incubated with glutathione seph-
arose (Thermo Scientific) and washed with PLC lysis
buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 10% gly-
cerol, 1% Triton X-100). SH2 proteins were eluted using
10 mM glutathione, 50 mM Tris HCl pH 8.0 and puri-
fied using the NAP-10 (Amersham Pharmacia) column
system.Peptide arrays
The peptide libraries were synthesized onto an acid
hardened amino-PEG500 cellulose membrane #UC540
(Intavis, Germany) using an Intavis Multipep as described
[41]. The estimated yield of peptide at each position was
approximately 5 nmols. Addressable peptide arrays repre-
senting physiological peptides were composed of 192
peptides, each composed of 11 amino acid residues,
corresponding to tyrosine-containing peptides from
InsR, IGF-1R, IRS-1, IRS-2, FGFR1, FGFR2, FGFR3,
FRS-2, FRS-3, PLCγ1, p130Cas, p62DOK1. Phospho-
tyrosine residues were located at the fifth position insingly phosphorylated peptides. In most cases Cys residues
were replaced with Ser. The membranes were stored
at −20 until use. The membranes were deprotected
according to manufacturer instructions, using a 95%
TFA, 3% TIPS, 2% H2O cocktail for three hours.
Phosphotyrosine incorporation was assessed by incubation
with anti-phosphotyrosine antisera 4 G10 (Upstate) and
pY20 (Santa Cruz). Additional file 1: Table S1 indi-
cates the array position, peptide sequence, protein source
position, and comments on related peptides and syn-
thesis problems.
SPOTs Analysis of SH2 domain specificities
All steps were carried out at room temperature unless
otherwise specified. The SPOTs membrane was first
blocked with 5% nonfat milk in TBS-T (0.1 M TrisHCl
(pH 7.4), 150 mM NaCl, and 0.1% Tween 20) overnight
at 4°C. GST alone or GST fusion proteins (0.25 μM)
were incubated with the SPOTs membrane in the same
buffer containing 1 mM DTT for 1½ hours at room
temperature and then washed with TBS-T. Anti-GST
(Amersham) antibodies were used to detect GST fusion
proteins and then incubated with anti-Goat Alexa-Fluor-
680 (Molecular Probes). The array membrane was sub-
sequently washed four times with TBS-T for 10 min.
Peptides that bound the domain of interest were visua-
lized by Li-Cor Odyssey using the 700 nm channel. In-
tensities were calculated using a grid with 192 circular
features of 2 mm diameter, each centered around a pep-
tide spot to avoid scoring SPOTs with halo or rings. For
each feature, the average (integrated) intensity was used
for downstream analysis.
Fluorescence polarization
Peptides were synthesized using FMOC-chemistry onto
pre-loaded tenta-gel resins. Peptides were then labeled
with Rhodamine B (Abbey Color) and then cleaved using
trifluoroacetic acid. Peptides were lyophilized and then
purified using a LC/MS (Agilent 2100). Dissociation
constants were measured using the Beacon 2000 (Invi-
trogen) as previously described [40].
Data analysis
All analysis steps were performed as previously described
[86]. Peptide intensity scores (excluding those defined as
non-specific) were averaged across each 192-peptide array,
producing an array mean. Array-positive binding was
ascribed to interactions with intensities greater than three
times the array mean. Peptide spots with average intensity
values between 1X-3X the array mean were defined as
‘indeterminate’. Those with intensities below 1X mean
were defined as array negative. Non-specific signal was
detected by arraying three separate 192 arrays with
three separate GST preps at 0.25 μM. Non-specific
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tensities greater than 3X the array mean in at least two of
three trials.
Phosphorylation status and solvent exposed tyrosines
The structures files of InsR (1IRK, 2DTG), IGF-1R (1P4O),
IRS-1 (1IRS, 1QQG), FGFR1 (1FGK), FGFR2 (2PVF),
FRS2 (1XR0), p62DOK1 (2 V76), PLCG1 (1HSQ, 2HSP)
collected from Protein Data Bank (PBD) (www.rcsb.org).
Surface accessible tyrosines were solved using the Gerstein
algorithm (http://helixweb.nih.gov/structbio/). The phos-
phorylation status of the 192 sites was identified using the
protein modification resource, Phosphosite (http://www.
phosphosite.org).
PSSMs and EDSM
For each SH2 domain a position specific scoring matrix
(PSSM) was calculated for the array-positive peptides
(posPSSM). A second PSSM was calculated for all
peptides, excluding those judged to be non-specific,
as the expected distribution of amino acids repre-
sented on the array (exPSSM). Subtracting exPSSM
from posPSSM yields the expectation deviation scor-
ing matrix or EDSM. The EDSM for each SH2 do-
main was visualized as a logo of positive and negative
factors using Weblogo [69].
EDSM clustering
The unbiased position specific expectation deviation
scoring matrix was expanded into a hyper-dimensional
vector representation, and the Euclidean distances
between vectors was computed. The resulting N-by-N
distance matrix was then clustered using the Fitch-
Margoliash method in the Phylip package [85]. The
unrooted tree was drawn using the MEGA package [86].
Reported interactions
Reported peptide interactions were collected by search-
ing HPRD and literature. Reported protein interactions
were collected from the major protein-protein inter-
action databases of MINT [50], BIND [51], HPRD [52],
and DIP [53] using UniHI [49].
Cells lines and GST-pull downs
Chinese Hamster Ovary (CHO) cells stably overexpressing
insulin receptor (InsR) and IRS-1 were graciously pro-
vided by Xiao Jian Sun (UChicago). CHO cells were grown
in DMEM/F12 supplemented with 10% fetal bovine
serum, penicillin and streptomycin. CHO cells were serum
starved for 24 hours and treated with and without insulin
(100 nM) for 5 mins. Cells were lysed in HNTG (20 mM
Hepes 7.5, NaCl, 1% Triton X-100, 10% Glycerol, 1 mM
NaV04) with protease inhibitors (1 mM PMSF, aprotonin
and leupeptin). Pre-cleared lysates were incubated withGST-SH2 domains immobilized on glutathione beads and
rocked for 3 hours at 4°C. Activated InsR and IRS-1 were
detected using anti-phosphotyrosine 4 G10 (Upstate).
Additional files
Additional file 1: This table includes the position of the peptide on
the array, peptide sequence, protein name, site of tyrosine
phosphorylation and the status of phosphorylation based on
Phosphosite (www.phosphosite.org). Information regarding whether
the peptide spot is considered “non-specific” is indicated. SH2 domains
that bound >3× and between 2× and 3× the mean are also listed.
Additional file 2: Supplementary materials includes a detailed
description of GST background removal, supplemental tables and
supplemental figures.
Additional file 3: Complete list of SH2 domains tested onto the
SPOT arrays.
Abbreviations
SH: Src Homology; Ins: Insulin; IGF: Insulin Growth Factor; FGF: Fibroblast
Growth Factor; HPRD: Human Protein Resource Database; PTK: Protein
Tyrosine Kinase; RTK: Receptor Tyrosine Kinase; PSSM: Position Specific
Scoring Matrix.
Competing interests
Both authors declare that they have no competing interests.
Authors’ contributions
BAL and PDN designed the study and drafted the manuscript; BAL, BWE, KH,
and ABS conducted the experiments. BAL, KJ and PDN developed the
methodologies and bioinformatic analysis. BAL, BWE, and ABS provided
analysis of the expression data. All authors read and approved the final
manuscript.
Acknowledgements
We gratefully acknowledge the helpful discussions of Tony Pawson, and
Michael Yaffé. We thank Kin Leung, Eshana Shah, Heather Schwartz and
Blerina Balliu for technical assistance. This work was supported by a grant
from the National Science Foundation (NSF MCB-0819125), a pilot project
grant from The University of Chicago Diabetes Research Training Center, a
grant from The Cancer Research Foundation and funds provided by The
University of Chicago Cancer Research Center (PDN). BAL was the recipient of
an Abbott Fellowship. The companion website (http://www.sh2domain.org)
was constructed by BAL.
Author details
1Ben May Department for Cancer Research, The University of Chicago,
Chicago, IL 60637, USA. 2Committee on Cancer Biology, The University of
Chicago, Chicago, IL 60637, USA. 3Department of Biochemistry and Molecular
Biology, The University of Chicago, Chicago, IL 60637, USA. 4Samuel
Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
5Department of Biomedical Informatics and Medical Education, University of
Washington, Seattle, WA, USA.
Received: 11 May 2012 Accepted: 1 August 2012
Published: 14 September 2012
References
1. van der Geer P, Hunter T, Lindberg RA: Receptor protein-tyrosine kinases
and their signal transduction pathways. Annu Rev Cell Biol 1994,
10:251–337.
2. Fantl WJ, Johnson DE, Williams LT: Signalling by receptor tyrosine kinases.
Annu Rev Biochem 1993, 62:453–481.
3. Lemmon MA, Schlessinger J: Cell signaling by receptor tyrosine kinases.
Cell 2010, 141:1117–1134.
4. Yaffe MB: Phosphotyrosine-binding domains in signal transduction. Nat
Rev Mol Cell Biol 2002, 3:177–186.
Liu et al. Cell Communication and Signaling 2012, 10:27 Page 21 of 23
http://www.biosignaling.com/content/10/1/275. Pawson T: Specificity in signal transduction: from phosphotyrosine-SH2
domain interactions to complex cellular systems. Cell 2004, 116:191–203.
6. Pawson T, Gish GD, Nash P: SH2 domains, interaction modules and
cellular wiring. Trends Cell Biol 2001, 11:504–511.
7. Matsuda M, Mayer BJ, Fukui Y, Hanafusa H: Binding of transforming
protein, P47gag-crk, to a broad range of phosphotyrosine-containing
proteins. Science 1990, 248:1537–1539.
8. Margolis B, Li N, Koch A, Mohammadi M, Hurwitz DR, Zilberstein A, Ullrich A,
Pawson T, Schlessinger J: The tyrosine phosphorylated carboxyterminus
of the EGF receptor is a binding site for GAP and PLC-gamma.
EMBO J 1990, 9:4375–4380.
9. Moran MF, Koch CA, Anderson D, Ellis C, England L, Martin GS, Pawson T:
Src homology region 2 domains direct protein-protein interactions in
signal transduction. Proc Natl Acad Sci USA 1990, 87:8622–8626.
10. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T: SH2 and SH3 domains:
elements that control interactions of cytoplasmic signaling proteins.
Science 1991, 252:668–674.
11. Liu BA, Engelmann BW, Nash PD: The language of SH2 domain
interactions defines phosphotyrosine-mediated signal transduction.
FEBS Lett 2012, 586:2597–2605.
12. Pawson T, Nash P: Assembly of cell regulatory systems through protein
interaction domains. Science 2003, 300:445–452.
13. Pawson T, Nash P: Protein-protein interactions define specificity in signal
transduction. Genes Dev 2000, 14:1027–1047.
14. Liu BA, Jablonowski K, Raina M, Arce M, Pawson T, Nash PD: The Human
and Mouse Complement of SH2 Domain Proteins-Establishing the
Boundaries of Phosphotyrosine Signaling. Mol Cell 2006, 22:851–868.
15. Liu BA, Shah E, Jablonowski K, Stergachis A, Engelmann BW, Nash PD: The
SH2 domain-containing proteins in 21 extant species establish the
provenance and scope of phosphotyrosine signaling in Eukaryotes.
Sci Signal 2011, 4:ra83.
16. Lappalainen I, Thusberg J, Shen B, Vihinen M: Genome wide analysis of
pathogenic SH2 domain mutations. Proteins 2008, 72:779–792.
17. Bradshaw JM, Mitaxov V, Waksman G: Investigation of phosphotyrosine
recognition by the SH2 domain of the Src kinase. J Mol Biol 1999,
293:971–985.
18. Bradshaw JM, Waksman G: Molecular recognition by SH2 domains.
Adv Protein Chem 2002, 61:161–210.
19. Songyang Z, Shoelson SE, Chaudhuri M, Gish G, Pawson T, Haser WG, King
F, Roberts T, Ratnofsky S, Lechleider RJ, et al: SH2 domains recognize
specific phosphopeptide sequences. Cell 1993, 72:767–778.
20. Huang H, Li L, Wu C, Schibli D, Colwill K, Ma S, Li C, Roy P, Ho K, Songyang
Z, et al: Defining the specificity space of the human SRC homology 2
domain. Mol Cell Proteomics 2008, 7:768–784.
21. Obenauer JC, Cantley LC, Yaffe MB: Scansite 2.0: Proteome-wide
prediction of cell signaling interactions using short sequence motifs.
Nucleic Acids Res 2003, 31:3635–3641.
22. Liu BA, Jablonowski K, Shah EE, Engelmann BW, Jones RB, Nash PD: SH2
domains recognize contextual peptide sequence information to
determine selectivity. Mol Cell Proteomics 2010, 9:2391–2404.
23. Machida K, Thompson CM, Dierck K, Jablonowski K, Karkkainen S, Liu B,
Zhang H, Nash PD, Newman DK, Nollau P, et al: High-throughput
phosphotyrosine profiling using SH2 domains. Mol Cell 2007, 26:899–915.
24. Dierck K, Machida K, Voigt A, Thimm J, Horstmann M, Fiedler W, Mayer BJ,
Nollau P: Quantitative multiplexed profiling of cellular signaling networks
using phosphotyrosine-specific DNA-tagged SH2 domains. Nat Methods
2006, 3:737–744.
25. Machida K, Mayer BJ: The SH2 domain: versatile signaling module and
pharmaceutical target. Biochim Biophys Acta 2005, 1747:1–25.
26. Machida K, Mayer BJ, Nollau P: Profiling the global tyrosine
phosphorylation state. Mol Cell Proteomics 2003, 2:215–233.
27. Machida K, Eschrich S, Li J, Bai Y, Koomen J, Mayer BJ, Haura EB:
Characterizing tyrosine phosphorylation signaling in lung cancer using
SH2 profiling. PLoS One 2010, 5:e13470.
28. Vetter SW, Zhang ZY: Probing the phosphopeptide specificities of protein
tyrosine phosphatases, SH2 and PTB domains with combinatorial library
methods. Curr Protein Pept Sci 2002, 3:365–397.
29. Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR,
Barbacid M, Sabe H, Hanafusa H, Yi T, et al: Specific motifs recognized by
the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav.
Mol Cell Biol 1994, 14:2777–2785.30. Rodriguez M, Li SS, Harper JW, Songyang Z: An oriented peptide array
library (OPAL) strategy to study protein-protein interactions.
J Biol Chem 2004, 279:8802–8807.
31. Cochrane D, Webster C, Masih G, McCafferty J: Identification of natural
ligands for SH2 domains from a phage display cDNA library.
J Mol Biol 2000, 297:89–97.
32. Panni S, Montecchi-Palazzi L, Kiemer L, Cabibbo A, Paoluzi S, Santonico E,
Landgraf C, Volkmer-Engert R, Bachi A, Castagnoli L, Cesareni G: Combining
peptide recognition specificity and context information for the
prediction of the 14–3–3-mediated interactome in S. cerevisiae and H.
sapiens. Proteomics 2011, 11:128–143.
33. Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villen
J, Haas W, Sowa ME, Gygi SP: A tissue-specific atlas of mouse protein
phosphorylation and expression. Cell 2010, 143:1174–1189.
34. Hlavacek WS, Faeder JR: The complexity of cell signaling and the need for
a new mechanics. Sci Signal 2009, 2:pe46.
35. Yang J, Hlavacek WS: Scaffold-mediated nucleation of protein signaling
complexes: Elementary principles. Math Biosci 2011, 232:164–173.
36. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M,
Zwahlen M, Kampf C, Wester K, Hober S, et al: Towards a knowledge-
based Human Protein Atlas. Nat Biotechnol 2010, 28:1248–1250.
37. Weiser AA, Or-Guil M, Tapia V, Leichsenring A, Schuchhardt J, Frommel C,
Volkmer-Engert R: SPOT synthesis: reliability of array-based measurement
of peptide binding affinity. Anal Biochem 2005, 342:300–311.
38. Katz C, Levy-Beladev L, Rotem-Bamberger S, Rito T, Rudiger SG, Friedler A:
Studying protein-protein interactions using peptide arrays. Chem Soc Rev
2011, 40:2131–2145.
39. Kramer A, Reineke U, Dong L, Hoffmann B, Hoffmuller U, Winkler D,
Volkmer-Engert R, Schneider-Mergener J: Spot synthesis: observations and
optimizations. J Pept Res 1999, 54:319–327.
40. Nash P, Tang X, Orlicky S, Chen Q, Gertler FB, Mendenhall MD, Sicheri
F, Pawson T, Tyers M: Multisite phosphorylation of a CDK inhibitor
sets a threshold for the onset of DNA replication. Nature 2001,
414:514–521.
41. Frank R: The SPOT-synthesis technique. Synthetic peptide arrays on
membrane supports--principles and applications. J Immunol Methods
2002, 267:13–26.
42. Frank R, Overwin H: SPOT synthesis. Epitope analysis with arrays of
synthetic peptides prepared on cellulose membranes. Methods Mol Biol
1996, 66:149–169.
43. Li SC, Gish G, Yang D, Coffey AJ, Forman-Kay JD, Ernberg I, Kay LE, Pawson
T: Novel mode of ligand binding by the SH2 domain of the human XLP
disease gene product SAP/SH2D1A. Curr Biol 1999, 9:1355–1362.
44. Mahrenholz CC, Tapia V, Stigler RD, Volkmer R: A study to assess the
cross-reactivity of cellulose membrane-bound peptides with detection
systems: an analysis at the amino acid level. J Pept Sci 2010, 16:297–302.
45. Myers MG Jr, Backer JM, Sun XJ, Shoelson S, Hu P, Schlessinger J, Yoakim M,
Schaffhausen B, White MF: IRS-1 activates phosphatidylinositol 3'-kinase
by associating with src homology 2 domains of p85. Proc Natl Acad Sci
USA 1992, 89:10350–10354.
46. Sun XJ, Pons S, Asano T, Myers MG Jr, Glasheen E, White MF: The Fyn
tyrosine kinase binds Irs-1 and forms a distinct signaling complex during
insulin stimulation. J Biol Chem 1996, 271:10583–10587.
47. Myers MG Jr, Zhang Y, Aldaz GA, Grammer T, Glasheen EM, Yenush L, Wang
LM, Sun XJ, Blenis J, Pierce JH, White MF: YMXM motifs and signaling by
an insulin receptor substrate 1 molecule without tyrosine
phosphorylation sites. Mol Cell Biol 1996, 16:4147–4155.
48. Sadowski I, Stone JC, Pawson T: A noncatalytic domain conserved among
cytoplasmic protein-tyrosine kinases modifies the kinase function and
transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol
1986, 6:4396–4408.
49. Chaurasia G, Iqbal Y, Hanig C, Herzel H, Wanker EE, Futschik ME: UniHI: an
entry gate to the human protein interactome. Nucleic Acids Res 2007,
35:D590–D594.
50. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, Castagnoli
L, Cesareni G: MINT: the Molecular INTeraction database. Nucleic Acids Res
2007, 35:D572–D574.
51. Bader GD, Betel D, Hogue CW: BIND: the Biomolecular Interaction
Network Database. Nucleic Acids Res 2003, 31:248–250.
52. Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, Bala P,
Shivakumar K, Anuradha N, Reddy R, Raghavan TM, et al: Human
Liu et al. Cell Communication and Signaling 2012, 10:27 Page 22 of 23
http://www.biosignaling.com/content/10/1/27protein reference database–2006 update. Nucleic Acids Res 2006,
34:D411–D414.
53. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, Eisenberg D: The
Database of Interacting Proteins: 2004 update. Nucleic Acids Res 2004,
32:D449–D451.
54. Liu BA, Engelmann BW, Nash PD: High-throughput analysis of peptide
binding modules. Proteomics 2012, 12:1527–1546.
55. Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W, Dionne CA,
Jaye M, Rubinstein M, Schlessinger J: A tyrosine-phosphorylated carboxy-
terminal peptide of the fibroblast growth factor receptor (Flg) is a
binding site for the SH2 domain of phospholipase C-gamma 1.
Mol Cell Biol 1991, 11:5068–5078.
56. Peters KG, Marie J, Wilson E, Ives HE, Escobedo J, Del Rosario M, Mirda D,
Williams LT: Point mutation of an FGF receptor abolishes
phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature
1992, 358:678–681.
57. Kaushansky A, Gordus A, Chang B, Rush J, MacBeath G: A quantitative
study of the recruitment potential of all intracellular tyrosine residues on
EGFR, FGFR1 and IGF1R. Mol Biosyst 2008, 4:643–653.
58. Jones RB, Gordus A, Krall JA, MacBeath G: A quantitative protein
interaction network for the ErbB receptors using protein microarrays.
Nature 2006, 439:168–174.
59. Bock I, Kudithipudi S, Tamas R, Kungulovski G, Dhayalan A, Jeltsch A:
Application of Celluspots peptide arrays for the analysis of the binding
specificity of epigenetic reading domains to modified histone tails.
BMC Biochem 2011, 12:48.
60. Stiffler MA, Chen JR, Grantcharova VP, Lei Y, Fuchs D, Allen JE, Zaslavskaia
LA, MacBeath G: PDZ domain binding selectivity is optimized across the
mouse proteome. Science 2007, 317:364–369.
61. Kaushansky A, Allen JE, Gordus A, Stiffler MA, Karp ES, Chang BH, MacBeath
G: Quantifying protein-protein interactions in high throughput using
protein domain microarrays. Nat Protoc 2010, 5:773–790.
62. Chang BH, Gujral TS, Karp ES, BuKhalid R, Grantcharova VP, MacBeath G: A
systematic family-wide investigation reveals that 30% of mammalian
PDZ domains engage in PDZ-PDZ interactions. Chem Biol 2011,
18:1143–1152.
63. Liu SK, Fang N, Koretzky GA, McGlade CJ: The hematopoietic-specific
adaptor protein gads functions in T-cell signaling via interactions with
the SLP-76 and LAT adaptors. Curr Biol 1999, 9:67–75.
64. Feng GS, Ouyang YB, Hu DP, Shi ZQ, Gentz R, Ni J: Grap is a novel SH3-
SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras
pathway. J Biol Chem 1996, 271:12129–12132.
65. Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B: PhosphoSite: A
bioinformatics resource dedicated to physiological protein
phosphorylation. Proteomics 2004, 4:1551–1561.
66. Videlock EJ, Chung VK, Hall JM, Hines J, Agapakis CM, Austin DJ:
Identification of a molecular recognition role for the activation loop
phosphotyrosine of the SRC tyrosine kinase. J Am Chem Soc 2005,
127:1600–1601.
67. Gerstein M, Chothia C: Packing at the protein-water interface. Proc Natl
Acad Sci USA 1996, 93:10167–10172.
68. Tsai J, Taylor R, Chothia C, Gerstein M: The packing density in proteins:
standard radii and volumes. J Mol Biol 1999, 290:253–266.
69. Crooks GE, Hon G, Chandonia JM, Brenner SE: WebLogo: a sequence logo
generator. Genome Res 2004, 14:1188–1190.
70. Liu BA, Nash PD: Evolution of SH2 domains and phosphotyrosine
signaling networks. Philos Trans R Soc Lond B Biol Sci 2012, 367:2555–2572.
71. Bisson N, James DA, Ivosev G, Tate SA, Bonner R, Taylor L, Pawson T:
Selected reaction monitoring mass spectrometry reveals the dynamics
of signaling through the GRB2 adaptor. Nat Biotechnol 2011, 29:653–658.
72. Gallagher EJ, LeRoith D: The proliferating role of insulin and insulin-like
growth factors in cancer. Trends Endocrinol Metab 2010, 21:610–618.
73. Siddle K: Signalling by insulin and IGF receptors: supporting acts and
new players. J Mol Endocrinol 2011, 47:R1–R10.
74. Heidegger I, Pircher A, Klocker H, Massoner P: Targeting the insulin-like
growth factor network in cancer therapy. Cancer Biol Ther 2011,
11:701–707.
75. Pansuria M, Xi H, Li L, Yang XF, Wang H: Insulin resistance, metabolic
stress, and atherosclerosis. Front Biosci (Schol Ed) 2012, 4:916–931.
76. Kim B, Feldman EL: Insulin resistance in the nervous system. Trends
Endocrinol Metab 2012, 23:133–141.77. Bradshaw JM, Waksman G: Calorimetric examination of high-affinity Src
SH2 domain-tyrosyl phosphopeptide binding: dissection of the
phosphopeptide sequence specificity and coupling energetics.
Biochemistry 1999, 38:5147–5154.
78. Lemmon MA, Ladbury JE, Mandiyan V, Zhou M, Schlessinger J:
Independent binding of peptide ligands to the SH2 and SH3 domains of
Grb2. J Biol Chem 1994, 269:31653–31658.
79. Piccione E, Case RD, Domchek SM, Hu P, Chaudhuri M, Backer JM,
Schlessinger J, Shoelson SE: Phosphatidylinositol 3-kinase p85 SH2
domain specificity defined by direct phosphopeptide/SH2 domain
binding. Biochemistry 1993, 32:3197–3202.
80. Hunter T, Cooper JA: Protein-tyrosine kinases. Annu Rev Biochem 1985,
54:897–930.
81. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy
B, Gandhi TK, Chandrika KN, Deshpande N, Suresh S, et al: Human protein
reference database as a discovery resource for proteomics. Nucleic Acids
Res 2004, 32:D497–D501.
82. Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jorgensen C, Miron IM,
Diella F, Colwill K, Taylor L, Elder K, et al: Systematic discovery of in vivo
phosphorylation networks. Cell 2007, 129:1415–1426.
83. Zarrinpar A, Park SH, Lim WA: Optimization of specificity in a cellular
protein interaction network by negative selection. Nature 2003,
426:676–680.
84. Mayer BJ, Hamaguchi M, Hanafusa H: A novel viral oncogene with
structural similarity to phospholipase C. Nature 1988, 332:272–275.
85. Felsenstein J: PHYLIP – Phylogeny Inference Package (Version 3.2).
Cladistics 1989, 5:164–166.
86. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary
Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007,
24:1596–1599.
87. Shin NY, Dise RS, Schneider-Mergener J, Ritchie MD, Kilkenny DM, Hanks SK:
Subsets of the major tyrosine phosphorylation sites in Crk-associated
substrate (CAS) are sufficient to promote cell migration. J Biol Chem 2004,
279:38331–38337.
88. Sawasdikosol S, Chang JH, Pratt JC, Wolf G, Shoelson SE, Burakoff SJ:
Tyrosine-phosphorylated Cbl binds to Crk after T cell activation.
J Immunol 1996, 157:110–116.
89. Howlett CJ, Bisson SA, Resek ME, Tigley AW, Robbins SM: The proto-
oncogene p120(Cbl) is a downstream substrate of the Hck protein-
tyrosine kinase. Biochem Biophys Res Commun 1999, 257:129–138.
90. Hunter S, Burton EA, Wu SC, Anderson SM: Fyn associates with Cbl and
phosphorylates tyrosine 731 in Cbl, a binding site for
phosphatidylinositol 3-kinase. J Biol Chem 1999, 274:2097–2106.
91. Frese S, Schubert WD, Findeis AC, Marquardt T, Roske YS, Stradal TE, Heinz
DW: The phosphotyrosine peptide binding specificity of Nck1 and Nck2
Src homology 2 domains. J Biol Chem 2006, 281:18236–18245.
92. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ Jr,
Backer JM, Ullrich A, White MF, et al: The SH2/SH3 domain-containing
protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc:
implications for insulin control of ras signalling. EMBO J 1993,
12:1929–1936.
93. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A,
Thomas S, Brugge J, Pelicci PG, et al: Association of the Shc and Grb2/
Sem5 SH2-containing proteins is implicated in activation of the Ras
pathway by tyrosine kinases. Nature 1992, 360:689–692.
94. Muller K, Gombert FO, Manning U, Grossmuller F, Graff P, Zaegel H, Zuber JF,
Freuler F, Tschopp C, Baumann G: Rapid identification of phosphopeptide
ligands for SH2 domains. Screening of peptide libraries by fluorescence-
activated bead sorting. J Biol Chem 1996, 271:16500–16505.
95. Ottinger EA, Botfield MC, Shoelson SE: Tandem SH2 domains confer high
specificity in tyrosine kinase signaling. J Biol Chem 1998, 273:729–735.
96. Pascal SM, Singer AU, Gish G, Yamazaki T, Shoelson SE, Pawson T, Kay LE,
Forman-Kay JD: Nuclear magnetic resonance structure of an SH2 domain
of phospholipase C-gamma 1 complexed with a high affinity binding
peptide. Cell 1994, 77:461–472.
97. Finerty PJ Jr, Mittermaier AK, Muhandiram R, Kay LE, Forman-Kay JD: NMR
dynamics-derived insights into the binding properties of a peptide
interacting with an SH2 domain. Biochemistry 2005, 44:694–703.
98. Malabarba MG, Milia E, Faretta M, Zamponi R, Pelicci PG, Di Fiore PP: A
repertoire library that allows the selection of synthetic SH2s with altered
binding specificities. Oncogene 2001, 20:5186–5194.
Liu et al. Cell Communication and Signaling 2012, 10:27 Page 23 of 23
http://www.biosignaling.com/content/10/1/2799. Moores SL, Selfors LM, Fredericks J, Breit T, Fujikawa K, Alt FW, Brugge JS,
Swat W: Vav family proteins couple to diverse cell surface receptors. Mol
Cell Biol 2000, 20:6364–6373.
100. Morra M, Lu J, Poy F, Martin M, Sayos J, Calpe S, Gullo C, Howie D, Rietdijk S,
Thompson A, et al: Structural basis for the interaction of the free SH2
domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J 2001,
20:5840–5852.
101. Zhou MM, Meadows RP, Logan TM, Yoon HS, Wade WS, Ravichandran KS,
Burakoff SJ, Fesik SW: Solution structure of the Shc SH2 domain
complexed with a tyrosine-phosphorylated peptide from the T-cell
receptor. Proc Natl Acad Sci USA 1995, 92:7784–7788.
102. Symes A, Stahl N, Reeves SA, Farruggella T, Servidei T, Gearan T,
Yancopoulos G, Fink JS: The protein tyrosine phosphatase SHP-2
negatively regulates ciliary neurotrophic factor induction of gene
expression. Curr Biol 1997, 7:697–700.
103. Yeh RH, Lee TR, Lawrence DS: From consensus sequence peptide to high
affinity ligand, a "library scan" strategy. J Biol Chem 2001,
276:12235–12240.
104. Boomer JS, Tan TH: Functional interactions of HPK1 with adaptor
proteins. J Cell Biochem 2005, 95:34–44.
105. Kayali AG, Eichhorn J, Haruta T, Morris AJ, Nelson JG, Vollenweider P, Olefsky
JM, Webster NJ: Association of the insulin receptor with phospholipase
C-gamma (PLCgamma) in 3 T3-L1 adipocytes suggests a role for
PLCgamma in metabolic signaling by insulin. J Biol Chem 1998,
273:13808–13818.
106. Lee CH, Li W, Nishimura R, Zhou M, Batzer AG, Myers MG Jr: White MF,
Schlessinger J, Skolnik EY: Nck associates with the SH2 domain-docking
protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci USA 1993,
90:11713–11717.
107. Case RD, Piccione E, Wolf G, Benett AM, Lechleider RJ, Neel BG, Shoelson SE:
SH-PTP2/Syp SH2 domain binding specificity is defined by direct
interactions with platelet-derived growth factor beta-receptor, epidermal
growth factor receptor, and insulin receptor substrate-1-derived
phosphopeptides. J Biol Chem 1994, 269:10467–10474.
108. Sun XJ, Crimmins DL, Myers MG Jr, Miralpeix M, White MF: Pleiotropic
insulin signals are engaged by multisite phosphorylation of IRS-1. Mol
Cell Biol 1993, 13:7418–7428.
109. Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B,
Schlessinger J: The function of GRB2 in linking the insulin receptor to Ras
signaling pathways. Science 1993, 260:1953–1955.
110. Myers MG Jr, Mendez R, Shi P, Pierce JH, Rhoads R, White MF: The COOH-
terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and
negatively regulate insulin signaling. J Biol Chem 1998, 273:26908–26914.
111. Sozzani P, Hasan L, Seguelas MH, Caput D, Ferrara P, Pipy B, Cambon C:
IL-13 induces tyrosine phosphorylation of phospholipase C gamma-1
following IRS-2 association in human monocytes: relationship with the
inhibitory effect of IL-13 on ROI production. Biochem Biophys Res Commun
1998, 244:665–670.
112. Patti ME, Sun XJ, Bruening JC, Araki E, Lipes MA, White MF, Kahn CR: 4PS/
insulin receptor substrate (IRS)-2 is the alternative substrate of the
insulin receptor in IRS-1-deficient mice. J Biol Chem 1995,
270:24670–24673.
113. Cross MJ, Lu L, Magnusson P, Nyqvist D, Holmqvist K, Welsh M, Claesson-
Welsh L: The Shb adaptor protein binds to tyrosine 766 in the FGFR-1
and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in
endothelial cells. Mol Biol Cell 2002, 13:2881–2893.
114. Kong M, Wang CS, Donoghue DJ: Interaction of fibroblast growth factor
receptor 3 and the adapter protein SH2-B. A role in STAT5 activation.
J Biol Chem 2002, 277:15962–15970.
115. Vainikka S, Joukov V, Wennstrom S, Bergman M, Pelicci PG, Alitalo K: Signal
transduction by fibroblast growth factor receptor-4 (FGFR-4).
Comparison with FGFR-1. J Biol Chem 1994, 269:18320–18326.
116. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I,
Schlessinger J: A lipid-anchored Grb2-binding protein that links
FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997,
89:693–702.
117. Hadari YR, Kouhara H, Lax I, Schlessinger J: Binding of Shp2 tyrosine
phosphatase to FRS2 is essential for fibroblast growth factor-induced
PC12 cell differentiation. Mol Cell Biol 1998, 18:3966–3973.
118. Poulin B, Sekiya F, Rhee SG: Intramolecular interaction between
phosphorylated tyrosine-783 and the C-terminal Src homology 2 domainactivates phospholipase C-gamma1. Proc Natl Acad Sci USA 2005,
102:4276–4281.
119. Schlaepfer DD, Broome MA, Hunter T: Fibronectin-stimulated signaling
from a focal adhesion kinase-c-Src complex: involvement of the Grb2,
p130cas, and Nck adaptor proteins. Mol Cell Biol 1997, 17:1702–1713.
120. Abassi YA, Rehn M, Ekman N, Alitalo K, Vuori K: p130Cas Couples the
tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and
cell migration. J Biol Chem 2003, 278:35636–35643.
121. Nasertorabi F, Tars K, Becherer K, Kodandapani R, Liljas L, Vuori K, Ely KR:
Molecular basis for regulation of Src by the docking protein p130Cas.
J Mol Recognit 2006, 19:30–38.
122. Kashige N, Carpino N, Kobayashi R: Tyrosine phosphorylation of p62dok
by p210bcr-abl inhibits RasGAP activity. Proc Natl Acad Sci USA 2000,
97:2093–2098.
123. Wick MJ, Dong LQ, Hu D, Langlais P, Liu F: Insulin receptor-mediated
p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct
roles for binding GTPase-activating protein and Nck and is essential for
inhibiting insulin-stimulated activation of Ras and Akt. J Biol Chem 2001,
276:42843–42850.
124. Lock P, Casagranda F, Dunn AR: Independent SH2-binding sites mediate
interaction of Dok-related protein with RasGTPase-activating protein and
Nck. J Biol Chem 1999, 274:22775–22784.
doi:10.1186/1478-811X-10-27
Cite this article as: Liu et al.: SRC Homology 2 Domain Binding Sites in
Insulin, IGF-1 and FGF receptor mediated signaling networks reveal an
extensive potential interactome. Cell Communication and Signaling 2012
10:27.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
